FOUNDATIONONE®CDx

PATIENT
Tung, Yu-Chieh

TUMOR TYPE
Brain glioblastoma (GBM)
COUNTRY CODE
TW

REPORT DATE
22 Feb 2022
ORDERED TEST #
ORD-1301522-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Brain glioblastoma (GBM)
NAME Tung, Yu-Chieh
DATE OF BIRTH 15 June 1968
SEX Female
MEDICAL RECORD # 11015080

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Brain
SPECIMEN ID S111-03814A (PF22015)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 24 January 2022
SPECIMEN RECEIVED 14 February 2022

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 0 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

NF1 Y2285fs*5
PIK3R1 G376R
CDKN2A/B CDKN2B loss, CDKN2A loss
MTAP loss
TERT promoter -124C>T

3 Disease relevant genes with no reportable alterations: ***EGFR, IDH1, PDGFRA***

† See About the Test in appendix for details.

Report Highlights

- Variants with **diagnostic implications** that may indicate a specific cancer type: ***TERT* promoter -124C>T** (p. 7)
- Targeted therapies with potential clinical benefit **approved in another tumor type**: Selumetinib (p. 8), Trametinib (p. 8)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 9)
- Variants with **prognostic implications** for this tumor type that may impact treatment decisions: ***TERT* promoter -124C>T** (p. 7)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	**No therapies or clinical trials.** see Biomarker Findings section	
Tumor Mutational Burden - 0 Muts/Mb	**No therapies or clinical trials.** see Biomarker Findings section	
GENOMIC FINDINGS	**THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)**	**THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)**
***NF1* -** Y2285fs*5	none	Selumetinib
10 Trials see p. 9		Trametinib
***PIK3R1* -** G376R	none	none
2 Trials see p. 11		

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

CDKN2A/B - CDKN2B loss, CDKN2A loss ..... p. 5
MTAP - loss ..... p. 6
TERT - promoter -124C>T ..... p. 7

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples[6-8]. A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples[6], although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs[9]. The frequency of MSI has been reported to be increased in relapsed compared to primary GBM[6], in GBMs with a previous lower grade astrocytoma[7], and in giant cell GBM compared to classic GBM[8].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[10]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[10-12]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[13-15]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[10,12,14-15].

BIOMARKER

Tumor Mutational Burden

RESULT
0 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[16-18], anti-PD-1 therapies[16-19], and combination nivolumab and ipilimumab[20-25]. In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported[16,26-27]. However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti-PD-1[28-29] or anti-PD-L1[30] therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.

FREQUENCY & PROGNOSIS

Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)[31]. For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB[32-33]. Increased TMB has been reported to correlate with higher tumor grade in glioma[34] and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD)[28], as well as with shorter OS of patients with diffuse glioma[35].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[36-37] and cigarette smoke in lung cancer[38-39], treatment with temozolomide-based chemotherapy in glioma[40-41], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[42-46], and microsatellite instability (MSI)[42,45-46]. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[16,26-30].

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
NF1

ALTERATION
Y2285fs*5

TRANSCRIPT ID
NM_001042492

CODING SEQUENCE EFFECT
6852_6855delTTAC

VARIANT ALLELE FREQUENCY (% VAF)
18.9%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in neurofibromatosis Type 1-associated neurofibroma[47-50], glioma or glioblastoma[50-54], and non-small cell lung cancer[55], NF1 inactivation may predict sensitivity to MEK inhibitors such as cobimetinib, trametinib, binimetinib, and selumetinib. Loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors, including everolimus and temsirolimus, based on limited clinical data[56-58] and strong preclinical data in models of malignant peripheral nerve sheath tumor (MPNST)[59-60]. A preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1-deficient MPNST[61]. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors[62], a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months[63].

FREQUENCY & PROGNOSIS

NF1 mutation has been observed in 5-6% of lower grade gliomas and 9-14% of glioblastoma multiforme (GBM) cases; homozygous deletion of NF1 was observed in 1% of lower grade gliomas and 2-3% of GBMs[40,64-66]. Among GBM subtypes, NF1 mutation and loss were reported most frequently in the mesenchymal subtype, 37% (14/28) and 38% (21/55) of cases, respectively[67]. NF1 loss was significantly associated with decreased overall and disease-specific survival in patients with lower grade gliomas (II-III), but not in those with GBM[68].

FINDING SUMMARY

NF1 encodes neurofibromin, a GTPase-activating protein (GAP) that is a key negative regulator of the RAS signaling pathway[69]. Neurofibromin acts as a tumor suppressor by repressing RAS signaling[70]. Alterations such as seen here may disrupt NF1 function or expression[70-79].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the NF1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with neurofibromatosis type 1 (ClinVar, Sep 2021)[80]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms[81-83]. Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,000[84-85], and in the appropriate clinical context, germline testing of NF1 is recommended.

GENE
PIK3R1

ALTERATION
G376R

TRANSCRIPT ID
NM_181523

CODING SEQUENCE EFFECT
1126G>A

VARIANT ALLELE FREQUENCY (% VAF)
21.4%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical[86-87] and preclinical[88-89] data, PIK3R1 alteration may predict sensitivity to pan-PI3K or PI3K-alpha-selective inhibitors. In patients with PIK3R1 mutation and no other alterations in the PI3K-AKT-mTOR pathway, 2 CRs have been achieved by patients with endometrial cancer treated with the pan-PI3K inhibitor pilaralisib[86], and 1 PR has been achieved by a patient with breast cancer treated with the PI3K-alpha inhibitor alpelisib in combination with ribociclib and letrozole[90]. Limited clinical and preclinical data suggest that PIK3R1 alterations may also be sensitive to inhibitors of mTOR[89,91-94] or AKT[95-96]. One preclinical study reported that PIK3R1 truncation mutations in the 299–370 range confer sensitivity to MEK inhibitors[97].

FREQUENCY & PROGNOSIS

One study detected PIK3R1 mutation in 10% (24/232) of IDH-wildtype glioblastoma (GBM) samples analyzed[98]. In the TCGA datasets, PIK3R1 mutation is most frequently observed in endometrial carcinoma (33%)[42], glioblastoma (GBM; 11%)[65], uterine carcinosarcoma (11%)(cBioPortal, Jan 2022)[99-100], and lower grade glioma (5%)[64]. PIK3R1 is often inactivated by in-frame insertions or deletions (indels), and the majority of this class of mutation (80%) was observed in endometrial carcinoma[101-103], although PIK3R1 indels have been reported in other cancer types such as GBM, cervical squamous cell carcinoma, and urothelial bladder carcinoma[101]. On the basis of limited clinical data, reduced PIK3R1 expression has been associated with reduced disease-free survival in prostate cancer[104] and metastasis-free survival in breast cancer[105]. PIK3R1 expression is not associated with overall survival in neuroendocrine tumors[106].

FINDING SUMMARY

PIK3R1 encodes the p85-alpha regulatory subunit of phosphatidylinositol 3-kinase (PI3K)[107]. Loss of PIK3R1 has been shown to result in increased PI3K signaling[108-111], promote tumorigenesis[88,95,108], and promote hyperplasia in the context of PTEN-deficiency[112]. Alterations such as seen here may disrupt PIK3R1 function or expression[89,96-97,102-103,113-122].

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
CDKN2A/B

ALTERATION
CDKN2B loss, CDKN2A loss

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib[123-126]. Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment[127-128], multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents[129-135]; it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors[136-137], the clinical relevance of p14ARF as a predictive biomarker is not clear. There are no drugs that directly target the mutation or loss of CDKN2B in cancer. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib[130,132-133,138-140].

FREQUENCY & PROGNOSIS

Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas[141] and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)[65] than in those with lower grade gliomas (13%) (cBioPortal, Sep 2021)[99-100]. In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM)[67,142-143]. A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF-encoding locus alone[144]. One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH-wildtype GBM samples analyzed[98]. Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples[145]. Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression[142,146]. In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas[147-148].

FINDING SUMMARY

CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b[149-150]. Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control[151-152]. The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition[153-154]. One or more alterations observed here are predicted to result in p16INK4a loss of function[155-176]. One or more alterations seen here are predicted to result in p14ARF loss of function[159,176-179]. CDKN2B alterations such as seen here are predicted to inactivate p15INK4b[180].

POTENTIAL GERMLINE IMPLICATIONS

Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer[181]. Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma[182-183]. CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases[184-186]. CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors[187-189]. In the appropriate clinical context, germline testing of CDKN2A is recommended.

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
MTAP

ALTERATION
loss

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical and limited clinical evidence indicate that MTAP inactivation produces specific metabolic vulnerabilities. MTAP inactivation may confer sensitivity to MAT2A inhibitors[190]. A Phase 1 trial of MAT2A inhibitor AG-270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss[191]. Although preclinical data have suggested that MTAP loss sensitizes cells to PRMT5 inhibition[190,192-193], MTAP loss may not be a biomarker of response to previously developed small-molecule SAM-uncompetitive PRMT5 inhibitors[194]; dual PRMT1 and PRMT5 inhibition may be more effective[195-197]. In preclinical cancer models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA, which is converted to adenine in normal cells, thereby providing competition to purine poisons lacking in MTAP-deficient cells[198-208]. A Phase 2 study of L-alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP-deficient cancers reported no responses and stable disease in 23.6% (13/55) of patients[209].

FREQUENCY & PROGNOSIS

MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers[210-211]; such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma[212], gastrointestinal stromal tumors[213], mantle cell lymphoma (MCL)[214], melanoma[215-216], gastric cancer[217], myxofibrosarcoma[218], nasopharyngeal carcinoma[219], ovarian carcinoma[210] and non-small cell lung cancer[220]. MTAP loss was not prognostic in pediatric B-cell acute lymphocytic leukemia[221] or in astrocytoma[222]. However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples[223], and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM[224]. Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma[225-226], esophageal cancer[227-228], osteosarcoma[229], and CRC[230].

FINDING SUMMARY

MTAP encodes S-methyl-5'-thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity[231-232]. Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment[212,233-234], thereby reducing intracellular arginine methylation[190,192,235] and altering cell signaling[234,236]. MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co-deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized.

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
TERT

ALTERATION
promoter -124C>T

TRANSCRIPT ID
NM_198253

CODING SEQUENCE EFFECT
-124C>T

VARIANT ALLELE FREQUENCY (% VAF)
26.3%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor-associated antigen and antisense oligonucleotide- or peptide-based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials[237]; however, in one preclinical study, the combination of a TERT peptide vaccine and anti-CTLA-4 therapy suppressed tumor growth[238]. A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non-small cell lung cancer reported no improvement in PFS or OS[239].

FREQUENCY & PROGNOSIS

TERT promoter mutations have been reported in 51-59% of gliomas[240-241], most frequently in glioblastoma (GBM, 54-84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25-31%) but less frequently in lower grade astrocytomas (10-18%) and in only 1% of ependymomas[240-244]. In patients with glioblastoma (GBM), the prevalence of TERT promoter mutation is lower in pediatric primary GBM (11%) and adult secondary GBM (28%) compared with adult primary GBM (58-83%)[240,242]. One study detected TERT promoter mutations in 78% (181/232) of IDH-wildtype GBM samples analyzed[98]. TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM[245]. TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH-positive secondary GBM[240,242,245-246]. In the context of IDH-wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v2.2021).

FINDING SUMMARY

Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length[247]. Activation of TERT is a hallmark of cancer, being detected in up to 80-90% of malignancies and absent in quiescent cells[248-250]. Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at -124 bp and -146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)[251-253], as well as tandem mutations at positions –124/–125 bp and –138/–139 bp[251].

POTENTIAL DIAGNOSTIC IMPLICATIONS

TERT mutations are associated with 1p/19q co-deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX-wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v5.2020). Co-occurring TERT mutation, IDH mutation, and 1p/19q co-deletion is indicative of oligodendroglioma, whereas IDH mutation in the absence of TERT mutation is suggestive of astrocytoma (NCCN CNS Cancers Guidelines, v5.2020).

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Selumetinib

Assay findings association

NF1
Y2285fs*5

AREAS OF THERAPEUTIC USE

Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PNs). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence in neurofibromatosis type 1 (NF1)-associated neurofibroma[47-50,254-258], glioma[50-54,259], and non-small cell lung cancer[55], NF1 inactivation may predict sensitivity to MEK inhibitors.

SUPPORTING DATA

Selumetinib has demonstrated clinical activity in low-grade glioma. A Phase 2 study of selumetinib for patients with low-grade glioma (LGG) reported 8/25 PRs for patients with BRAF alterations and 10/25 PRs for those with NF1-associated LGG[51]; a Phase 1 study of selumetinib reported 5/25 PRs for patients with LGG[260]. A Phase 2 study of selumetinib for patients with tumors with activating alterations in the MAPK pathway evaluated 8 patients with high-grade glioma (HGG); 2 SDs and no objective responses were observed in this subset[261]. Selumetinib has demonstrated efficacy in NF1-associated neurofibroma in Phase 2 studies[48,254-255] and a Phase 1 study[47]. Phase 2 studies reported clinical responses in low-grade glioma[51,260], melanoma[262-266], and in lung[55,267-268] and endometrial cancer[269]. A Phase 2 study of selumetinib for patients with activating alterations in the MAPK pathway reported a DCR of 15% (3/20), with no objective responses observed[261]. Phase 1 studies of selumetinib to treat patients with solid tumors reported 1/15 PR for a patient with colorectal cancer (CRC) and 5/15 SDs for patients with tonsil squamous cell carcinoma (SCC), non-small cell lung cancer (NSCLC), and CRC[270]; 2/39 PRs (for patients with CRC) and 18/39 SDs were achieved when selumetinib was administered in combination with cyclosporin A[271]. Multiple Phase 1 studies combining selumetinib with erlotinib or temsirolimus[272], docetaxel or dacarbazine[273], AKT inhibitors[274], or cixutumumab (an anti-IGF-1R antibody)[275] reported clinical responses for patients with advanced solid tumors including NSCLC, thyroid carcinoma, tongue SCC, and ovarian cancer.

Trametinib

Assay findings association

NF1
Y2285fs*5

AREAS OF THERAPEUTIC USE

Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence in neurofibromatosis type 1 (NF1)-associated neurofibroma[47-50,254-258], glioma[50-54,259], and non-small cell lung cancer[55], NF1 inactivation may predict sensitivity to MEK inhibitors.

SUPPORTING DATA

Case studies of trametinib in NF1-associated low-grade glioma have reported 7 PRs, including 2 patients with pilocytic astrocytoma, 2 patients with diffuse astrocytoma, 3 patients with low-grade glioma experiencing PRs of over 6 months[50,52-53,259]. A study of four pediatric patients with BRAF mutation-positive non-operable astrocytoma reported a reduction in tumor volume in response to trametinib for the 3 optic gliomas with BRAF duplication[276-277]. A patient with pilocytic astrocytoma harboring an NFIA-RAF1 fusion that had progressed on multiple lines of prior treatment exhibited ongoing SD following treatment with trametinib[278]. Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors[62], a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months[63].

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
NF1

ALTERATION
Y2285fs*5

RATIONALE
On the basis of clinical evidence and strong preclinical evidence, NF1 inactivation may predict sensitivity to MEK inhibitors. Limited clinical data and strong preclinical data indicate that loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors.

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT04337463

PHASE NULL

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

TARGETS
mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT03834740

PHASE NULL

Ph0/2 Ribociclib & Everolimus

TARGETS
CDK6, CDK4, mTOR

LOCATIONS: Arizona

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT03905148

PHASE 1/2

Study of the Safety and Pharmacokinetics of BGB-283 and PD-0325901 in Patients With Advanced or Refractory Solid Tumors

TARGETS
RAFs, EGFR, MEK

LOCATIONS: Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), Texas

NCT04185831

PHASE 2

A MolEcularly Guided Anti-Cancer Drug Off-Label Trial

TARGETS
PD-L1, MEK, mTOR

LOCATIONS: Uppsala (Sweden), Gothenburg (Sweden)

NCT03158389

PHASE 1/2

NCT Neuro Master Match - N^2M^2 (NOA-20)

TARGETS
ALK, RET, CDK4, CDK6, mTOR, MDM2, PD-L1, SMO

LOCATIONS: Berlin (Germany), Dresden (Germany), Regensburg (Germany), Bochum (Germany), Frankfurt am Main (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Cologne (Germany), Mannheim (Germany)

NCT03065062

PHASE 1

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

TARGETS
PI3K-alpha, PI3K-gamma, mTORC1, mTORC2, CDK4, CDK6

LOCATIONS: Massachusetts

NCT03162627

PHASE 1

Selumetinib and Olaparib in Solid Tumors

TARGETS
MEK, PARP

LOCATIONS: Texas

GENE
PIK3R1

ALTERATION
G376R

RATIONALE
On the basis of clinical and strong preclinical data, PIK3R1 loss or inactivation may indicate sensitivity to pan-PI3K or PI3K-alpha-selective inhibitors.

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT03711058

PHASE 1/2

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

TARGETS
PD-1, PI3K

LOCATIONS: Maryland

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

CREBBP
V238L

EP300
L765F

EPHB1
V891M

MAP3K1
L78P

MLH1
L259S

MLL2
Q3745_H3746insQ

MSH3
A62_P63insSAA

NBN
I35T

NKX2-1
S355L

NOTCH1
Q1134R

NOTCH2
R869Q

NTRK1
V13A

SETD2
E972Q

TEK
loss and rearrangement

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B)*	*APC*
AR	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*	*BTG2*
BTK	*C11orf30 (EMSY)*	*C17orf39 (GID4)*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*
CCND2	*CCND3*	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*
CDH1	*CDK12*	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FAM46C	*FANCA*	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*
FGF14	*FGF19*	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*
FGFR4	*FH*	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*
GATA4	*GATA6*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3F3A*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11A*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*	*P2RY8*	*PALB2*
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*	*PDGFRA*
PDGFRB	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*	*REL*	*RET*
RICTOR	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*	*SDHD*	*SETD2*
SF3B1	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*	*SNCAIP*	*SOCS1*
SOX2	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*	*STK11*	*SUFU*
SYK	*TBX3*	*TEK*	*TET2*	*TGFBR2*	*TIPARP*	*TNFAIP3*	*TNFRSF14*	*TP53*
TSC1	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*	*VHL*	*WHSC1*	*WT1*	*XPO1*
XRCC2	*ZNF217*	*ZNF703*						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV4*
ETV5	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*	*KMT2A (MLL)*
MSH2	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*	*RAF1*
RARA	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***	*TMPRSS2*

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-

Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
4. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
5. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
6. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear

cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 6.0.0

The median exon coverage for this sample is 939x

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Martinez R, et al. Oncology (2004) pmid: 15331927
7. Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285
8. Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554
9. Szybka M, et al. Clin. Neuropathol. () pmid: 12908754
10. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
11. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
12. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
13. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
14. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
15. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
16. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
17. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
18. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
19. Cristescu R, et al. Science (2018) pmid: 30309915
20. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
21. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
22. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
23. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
24. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
25. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
26. Zhao J, et al. Nat. Med. (2019) pmid: 30742119
27. Touat M, et al. Nature (2020) pmid: 32322066
28. Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570
29. Johanns TM, et al. Cancer Discov (2016) pmid: 27683556
30. Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642
31. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
32. Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112
33. Johnson A, et al. Oncologist (2017) pmid: 28912153
34. Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864
35. Wang L, et al. BMC Cancer (2020) pmid: 32164609
36. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
37. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
38. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
39. Rizvi NA, et al. Science (2015) pmid: 25765070
40. Johnson BE, et al. Science (2014) pmid: 24336570
41. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
42. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
43. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
44. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
45. Nature (2012) pmid: 22810696
46. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
47. Dombi E, et al. N. Engl. J. Med. (2016) pmid: 28029918
48. Schalkwijk S, et al. Cancer Chemother Pharmacol (2021) pmid: 33903938
49. Toledano H, et al. Childs Nerv Syst (2021) pmid: 33751171
50. Ronsley R, et al. Cancer Med (2021) pmid: 33939292
51. Fangusaro J, et al. Lancet Oncol. (2019) pmid: 31151904
52. Manoharan N, et al. J Neurooncol (2020) pmid: 32780261
53. Kondyli M, et al. J Neurooncol (2018) pmid: 30097824
54. Awada G, et al. Case Rep Oncol () pmid: 33082744
55. Middleton G, et al. Nature (2020) pmid: 32669708
56. Lim SM, et al. Oncotarget (2016) pmid: 26859683
57. Weiss B, et al. Neuro-oncology (2015) pmid: 25314964
58. Janku F, et al. Oncotarget (2014) pmid: 24931142
59. Johannessen CM, et al. Curr. Biol. (2008) pmid: 18164202
60. Johannessen CM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15937108
61. Malone CF, et al. Cancer Discov (2014) pmid: 24913553
62. Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362
63. Patterson et al., 2018; AACR Abstract 3891
64. Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751
65. Brennan CW, et al. Cell (2013) pmid: 24120142
66. Nature (2008) pmid: 18772890
67. Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251
68. Vizcaíno MA, et al. Hum. Pathol. (2015) pmid: 26190195
69. Hattori S, et al. Biochem. Biophys. Res. Commun. (1991) pmid: 1904223
70. Morcos P, et al. Mol. Cell. Biol. (1996) pmid: 8628317
71. Ballester R, et al. Cell (1990) pmid: 2121371
72. Xu GF, et al. Cell (1990) pmid: 2116237
73. Martin GA, et al. Cell (1990) pmid: 2121370
74. Thomas L, et al. Hum. Mutat. (2012) pmid: 22807134
75. Skuse GR, et al. Hum. Mol. Genet. (1997) pmid: 9300663
76. Messiaen LM, et al. Genet. Med. () pmid: 11258625
77. Ars E, et al. Hum. Mol. Genet. (2000) pmid: 10607834
78. Messiaen LM, et al. J. Med. Genet. (2005) pmid: 15863657
79. Poullet P, et al. Mol. Cell. Biol. (1994) pmid: 8264648
80. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
81. Jett K, et al. Genet. Med. (2010) pmid: 20027112
82. Patil S, et al. Oncologist (2012) pmid: 22240541
83. Evans DG, et al. Clin Sarcoma Res (2012) pmid: 23036231
84. Upadhyaya M, et al. J. Med. Genet. (1995) pmid: 8544190
85. Williams VC, et al. Pediatrics (2009) pmid: 19117870
86. Matulonis U, et al. Gynecol. Oncol. (2015) pmid: 25528496
87. Pitz MW, et al. Neuro-oncology (2015) pmid: 25605819
88. Thorpe LM, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) pmid: 28630349
89. Sun M, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20713702
90. Juric et al., 2016; SABCS Abstract P3-14-01
91. Basho RK, et al. JAMA Oncol (2017) pmid: 27893038
92. Myers AP, et al. Gynecol. Oncol. (2016) pmid: 27016228
93. Day TA, et al. Clin. Cancer Res. (2019) pmid: 30420444
94. Ou O, et al. Cancer Lett. (2014) pmid: 25193464
95. Li X, et al. Nat Commun (2019) pmid: 30755611
96. Quayle SN, et al. PLoS ONE (2012) pmid: 23166678
97. Cheung LW, et al. Cancer Cell (2014) pmid: 25284480
98. Yan et al. 2020; DOI:10.1200/PO.19.00385
99. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
100. Gao J, et al. Sci Signal (2013) pmid: 23550210
101. Ye K, et al. Nat. Med. (2016) pmid: 26657142
102. Cheung LW, et al. Cancer Discov (2011) pmid: 21984976
103. Urick ME, et al. Cancer Res. (2011) pmid: 21478295
104. Munkley J, et al. Oncoscience (2015) pmid: 26501081
105. Cizkova M, et al. BMC Cancer (2013) pmid: 24229379
106. Qian ZR, et al. J. Clin. Oncol. (2013) pmid: 23980085
107. Huang CH, et al. Cell Cycle (2008) pmid: 18418043
108. Taniguchi CM, et al. Cancer Res. (2010) pmid: 20530665
109. Luo J, et al. Cell Metab. (2006) pmid: 16679293
110. Ueki K, et al. J. Biol. Chem. (2003) pmid: 14504291
111. Mauvais-Jarvis F, et al. J. Clin. Invest. (2002) pmid: 11781359
112. Luo J, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 16006513
113. Jaiswal BS, et al. Cancer Cell (2009) pmid: 19962665
114. Ko HR, et al. Cell Death Dis (2014) pmid: 24651434
115. Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146
116. Huang CH, et al. Science (2007) pmid: 18079394
117. Bousquet C, et al. EMBO J. (2006) pmid: 16917505
118. Oliver MD, et al. Biosci. Rep. (2017) pmid: 28143957
119. Philp AJ, et al. Cancer Res. (2001) pmid: 11606375
120. Lucas CL, et al. J. Exp. Med. (2014) pmid: 25488983
121. Chen L, et al. Nat Commun (2018) pmid: 29636477
122. Li X, et al. Proc Natl Acad Sci U S A (2021) pmid: 34507989
123. Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246
124. Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868
125. Cen L, et al. Neuro-oncology (2012) pmid: 22711607
126. Logan JE, et al. Anticancer Res. (2013) pmid: 23898052
127. Elvin JA, et al. Oncologist (2017) pmid: 28283584
128. Gao J, et al. Curr Oncol (2015) pmid: 26715889
129. Gopalan et al., 2014; ASCO Abstract 8077
130. Peguero et al., 2016; ASCO Abstract 2528
131. Konecny et al., 2016; ASCO Abstract 5557
132. DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126
133. Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798
134. Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767
135. Johnson DB, et al. Oncologist (2014) pmid: 24797823
136. Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101
137. Gamble LD, et al. Oncogene (2012) pmid: 21725357
138. Shapiro et al., 2013; ASCO Abstract 2500
139. Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362
140. Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312
141. Ceccarelli M, et al. Cell (2016) pmid: 26824661
142. Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337
143. Weber RG, et al. Oncogene (2007) pmid: 16909113
144. Nakamura M, et al. Brain Pathol. (2001) pmid: 11303791
145. Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817
146. Feng J, et al. Cancer (2012) pmid: 21713760
147. Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552
148. Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312
149. Quelle DE, et al. Cell (1995) pmid: 8521522
150. Mutat. Res. (2005) pmid: 15878778
151. Gazzeri S, et al. Oncogene (1998) pmid: 9484839
152. Oncogene (1999) pmid: 10498883

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

153. Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746
154. Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699
155. Ruas M, et al. Oncogene (1999) pmid: 10498896
156. Jones R, et al. Cancer Res. (2007) pmid: 17909018
157. Haferkamp S, et al. Aging Cell (2008) pmid: 18843795
158. Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717
159. Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711
160. Gombart AF, et al. Leukemia (1997) pmid: 9324288
161. Yang R, et al. Cancer Res. (1995) pmid: 7780957
162. Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202
163. Greenblatt MS, et al. Oncogene (2003) pmid: 12606942
164. Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434
165. Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261
166. Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926
167. Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062
168. Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365
169. Koh J, et al. Nature (1995) pmid: 7777061
170. McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136
171. Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282
172. Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385
173. Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262
174. Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892
175. Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768
176. Rutter JL, et al. Oncogene (2003) pmid: 12853981
177. Itahana K, et al. Cancer Cell (2008) pmid: 18538737
178. Zhang Y, et al. Mol. Cell (1999) pmid: 10360174
179. Zhang Y, et al. Cell (1998) pmid: 9529249
180. Jafri M, et al. Cancer Discov (2015) pmid: 25873077
181. Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917
182. Adv Exp Med Biol (2010) pmid: 20687502
183. Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083
184. De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703
185. Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650
186. Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243
187. Kaufman DK, et al. Neurology (1993) pmid: 8414022
188. Bahuau M, et al. Cancer Res (1998) pmid: 9622062
189. Chan AK, et al. Clin Neuropathol () pmid: 28699883
190. Marjon K, et al. Cell Rep (2016) pmid: 27068473
191. Heist et al., 2019; AACR-NCI-EORTC Abstract B116
192. Mavrakis KJ, et al. Science (2016) pmid: 26912361
193. Endoscopy (1989) pmid: 2691236
194. Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521
195. Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072
196. Srour N, et al. Cancer Cell (2019) pmid: 31287990
197. Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320
198. Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154
199. Tang B, et al. Cancer Res. (2018) pmid: 29844120
200. Munshi PN, et al. Oncologist (2014) pmid: 24928612
201. de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376
202. Lubin M, et al. PLoS ONE (2009) pmid: 19478948
203. Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330
204. Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602
205. Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207
206. Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358
207. Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432
208. Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241
209. Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081
210. Wei R, et al. Sci Rep (2016) pmid: 27929028
211. Zhao M, et al. BMC Genomics (2016) pmid: 27556634
212. Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366
213. Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491
214. Marcé S, et al. Clin. Cancer Res. (2006) pmid: 16778103
215. Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769
216. Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867
217. Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930
218. Li CF, et al. Oncotarget (2014) pmid: 25426549
219. He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376
220. Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958
221. Mirebeau D, et al. Haematologica (2006) pmid: 16818274
222. Becker AP, et al. Pathobiology (2015) pmid: 26088413
223. Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286
224. Bistulfi G, et al. Oncotarget (2016) pmid: 26910893
225. Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435
226. Maccioni L, et al. BMC Cancer (2013) pmid: 23816148
227. Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288
228. Lin X, et al. Cancer Sci. (2017) pmid: 27960044
229. Zhi L, et al. J Cancer (2016) pmid: 27994653
230. Gu F, et al. Br. J. Cancer (2013) pmid: 23361049
231. Limm K, et al. PLoS ONE (2016) pmid: 27479139
232. Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827
233. Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702
234. Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084
235. Kryukov GV, et al. Science (2016) pmid: 26912360
236. Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184
237. Nat Rev Clin Oncol (2017) pmid: 27245281
238. Duperret EK, et al. Mol Ther (2018) pmid: 29249395
239. Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017
240. Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248
241. Killela PJ, et al. Oncotarget (2014) pmid: 24722048
242. Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565
243. Liu X, et al. Cell Cycle (2013) pmid: 23603989
244. Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961
245. Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841
246. Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890
247. Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685
248. Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118
249. Kim NW, et al. Science (1994) pmid: 7605428
250. Hanahan D, et al. Cell (2000) pmid: 10647931
251. Horn S, et al. Science (2013) pmid: 23348503
252. Huang FW, et al. Science (2013) pmid: 23348506
253. Vinagre J, et al. Nat Commun (2013) pmid: 23887589
254. Glassberg et al., 2020; ASPHO Abstract 2015
255. Coyne et al., 2020; ASCO Abstract 3612
256. McCowage et al., 2018; ASCO Abstract 10504
257. Mueller et al., 2020; SNO Abstract NFB-17
258. Waldner et al., 2020; DOI: 10.1055/s-0040-1715638
259. Romo et al., 2019; SNO Abstract RARE-54
260. Banerjee A, et al. Neuro-oncology (2017) pmid: 28339824
261. Allen et al., 2021; ASCO Abstract 10008
262. Gupta A, et al. Ann. Oncol. (2014) pmid: 24567366
263. Robert C, et al. Lancet Oncol. (2013) pmid: 23735514
264. Kirkwood JM, et al. Clin. Cancer Res. (2012) pmid: 22048237
265. Banerji U, et al. Clin. Cancer Res. (2010) pmid: 20179232
266. Boers-Sonderen MJ, et al. Anticancer Drugs (2012) pmid: 22293660
267. Lopez-Chavez A, et al. J. Clin. Oncol. (2015) pmid: 25667274
268. Hainsworth JD, et al. J Thorac Oncol (2010) pmid: 20802351
269. Coleman RL, et al. Gynecol. Oncol. (2015) pmid: 25887099
270. Deming DA, et al. Invest New Drugs (2016) pmid: 26666244
271. Krishnamurthy A, et al. Cancer Res. (2018) pmid: 30042150
272. Infante JR, et al. Invest New Drugs (2017) pmid: 28424891
273. LoRusso PM, et al. BMC Cancer (2017) pmid: 28264648
274. Tolcher AW, et al. Clin. Cancer Res. (2015) pmid: 25516890
275. Wilky BA, et al. Br. J. Cancer (2015) pmid: 25268371
276. Miller et al., 2016; ISPNO Abstract LG-01
277. Miller C, et al. J Neurosurg Pediatr (2017) pmid: 28009226
278. Yde CW, et al. Cancer Genet (2016) pmid: 27810072

Electronically signed by Matthew Hiemenz, M.D. | 22 February 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531